REporting recommendations for tumor MARKer prognostic studies (REMARK)

By for the Statistics Subcommittee of the NCI—EORTC Worki Diagnostics. Nature Clinical Practice Oncology, 2005

2,421 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/ce8395fbfd7fb0da80b428b95330b85f8c34a3ee

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

In Oncology

Citations in the corpus

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary (2010, background): “Furthermore, aCGH analysis of cases 533 and 60214 did not show high-frequency DCNAs that are typical of HGPSC [11].”
Effect of Ebola Progression in Liberia (2015, neutral): “TRIPOD is not intended for multivariable modeling in etiologic studies or for studies investigating single prognostic factors (37).”
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement (2015, neutral): “TRIPOD is not intended for multivariable modeling in etiologic studies or for studies investigating single prognostic factors [37].”
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. (2012, positive): “As such, we defined our thresholds based on rational statistical methods in accordance with recommended guidelines.(36) Our BCL2 threshold compares favorably with that defined by Tzankov et al,(34) who used receiver operator curves to define optimal cutoff scores, but it is lower than the 75% thresh”
Assessing Bias in Studies of Prognostic Factors (2013, methodology): “One team described combining the QUIPS recommendations with the items from the Reporting Recommendations for Tumour Marker Prognostic Studies reporting guidelines (31), and 2 review groups referred to versions from other authors (for example, the National Institute for Health and Clinical Excellence”
Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring (2012, background): “Appropriately powered studies to validate initial results of genomics studies often are lacking [5] or fail to confirm initial discovery-phase results [6], limiting clinical implementation of new disease biomarkers.”
Identification of metastasis‐related microRNAs in hepatocellular carcinoma (2008, neutral): “823 Multinodular No 189 (78) 121 (92) 68 (62) Yes 52 (22) 10 (8) 42 (38) <0.”
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration (2015, background): “Reporting guidelines for randomized trials (CONSORT [96]), observational studies (STROBE [97]), tumor marker studies (REMARK [98]), molecular epidemiology (STROBE-ME [99]), diagnostic accuracy (STARD [100]), and genetic risk prediction studies (GRIPS [101]) contain items that are relevant to all typ”